Strong Albumin Solutions in Patients With Septic Shock

Summary

Sepsis is an increasingly recognised burden to healthcare systems worldwide. Intravenous fluid therapy is a common first-line intervention recommended by international guidelines. Hyperoncotic preparations of human albumin solution are widely available, but their efficacy has yet to be proven. This randomised feasibility trial will test whether it is feasible to administer hyperoncotic albumin solutions as both fluid resuscitation and as a regular supplement in patients with early septic shock.

Timeline

Start

2023-11-10

Primary completion

2025-04-05

Completion

2026-01-31

Drugs

Indications